It is hypothesized that with continued use and continued titration of insulin, superior reductions in A1C would be seen with an intensive insulin therapy compared to GLP-1 RAs
How This Blind Spot Leads Directly Into the Next Crisis If we cannot explain how GLP-1 agonists exert their multi-system effects, then we cannot reliably determine who benefits from them, why certain responses emerge, or which biological signatures distinguish durable responders from partial responders, early plateauers, non-responders, or individuals at risk for muscle loss, inflammatory rebound, or neuroprotective divergence
10.1007/s13346-017-0398-z 55 EbanksJ
Getting good sleep is important for your childs development and well-being
Your body as a vehicle: the carnitine car analogy For the sake of illustration, let's think of the body like a car